Immunotherapy

You have access
Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular Immunotherapy
MASAFUMI IGUCHI, SHIGEKI YAGYU, KOSUKE KAMBE, MAYUMI HIGASHI, SHIGEHISA FUMINO, TSUNAO KISHIDA, TOMOKO IEHARA, OSAM MAZDA and TATSURO TAJIRI

Anticancer Research June 2023, 43 (6) 2417-2424; DOI: https://doi.org/10.21873/anticanres.16409
You have access
Differential Effects of Anti-PD-1/PD-L1 Checkpoint Inhibitors on Adhesion Molecules and Cytokine Secretion by THP-1 Monocytes
EVA PROBST, KLAAS F. FRANZEN, CHRISTIAN IDEL, KIRSTIN PLÖTZE-MARTIN, JONAS FLECKNER, DIRK RADES, SABINE BOHNET, KARL-LUDWIG BRUCHHAGE and RALPH PRIES

Anticancer Research June 2023, 43 (6) 2445-2454; DOI: https://doi.org/10.21873/anticanres.16412
You have access
Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
HYERA KIM, DONG HYUN LIM, YONG SHIK KWON, MI AE KIM and KEON UK PARK

Anticancer Research May 2023, 43 (5) 2343-2349; DOI: https://doi.org/10.21873/anticanres.16399
Open Access
A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway
ERLINDA M. GORDON, NICOLE L. ANGEL, NADEZHDA OMELCHENKO, VICTORIA S. CHUA-ALCALA, ANIA MORADKHANI, DORIS QUON and STEVEN WONG

Anticancer Research May 2023, 43 (5) 1993-2002; DOI: https://doi.org/10.21873/anticanres.16360
You have access
Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data
KENJI NAKAHAMA, MOTOHIRO IZUMI, NAOKI YOSHIMOTO, MITSURU FUKUI, AKIRA SUGIMOTO, HIROAKI NAGAMINE, KOICHI OGAWA, KENJI SAWA, YOKO TANI, HIROYASU KANEDA, SHIGEKI MITSUOKA, TETSUYA WATANABE, KAZUHISA ASAI and TOMOYA KAWAGUCHI

Anticancer Research May 2023, 43 (5) 2185-2197; DOI: https://doi.org/10.21873/anticanres.16381
You have access
Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs. Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population
LOLA MACIA-RIVAS, CLARA LUZ FERNANDEZ-LAGUNA, CRISTINA ALVAREZ-ASTEINZA, IVAN MARAY, MONICA CARBAJALES-ALVAREZ and ANA LOZANO-BLAZQUEZ

Anticancer Research April 2023, 43 (4) 1681-1688; DOI: https://doi.org/10.21873/anticanres.16320
Open Access
Efficacy of Multimodality Approach in Patients With Recurrent Head and Neck Squamous Cell Carcinoma
PASCALE ALICIA HOELL, KHALED ELSAYAD, HENDRIK BERSSENBRUEGGE, DOMINIK HERING, CHRISTOPHER KITTEL, JOHANNES KLEINHEINZ, ANNALEN BLECKMANN, GEORG EVERS, EVA WARDELMANN, CLAUDIA RUDACK and HANS THEODOR EICH

Anticancer Research March 2023, 43 (3) 1255-1263; DOI: https://doi.org/10.21873/anticanres.16272
Open Access
Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
SANDRO M. WAGNER, TERESA MAGNES, THOMAS MELCHARDT, DOMINIK KIEM, LUKAS WEISS, DANIEL NEUREITER, CHRISTINA WAGNER, MARIE-BERNADETTE ARETIN, STEFAN NEMEC, GABRIELE GAMERITH, GEORG PALL, RICHARD GREIL and THORSTEN FUEREDER

Anticancer Research March 2023, 43 (3) 1273-1282; DOI: https://doi.org/10.21873/anticanres.16274
Open Access
Use of Conditioned Extracellular Matrix as a Tissue-engineered Tumor Matrisome for Prostate Cancer and Melanoma Immunotherapy
MARK A. SUCKOW and MICHAEL C. HILES

Anticancer Research January 2023, 43 (1) 335-341; DOI: https://doi.org/10.21873/anticanres.16168
You have access
Impact of Corticosteroids for IrAEs on the Clinical Outcome of Immunotherapy in Patients With NSCLC
KAZUHIRO SHIMOMURA, TEPPEI YAMAGUCHI, YUKO OYA, KOSAKU UCHIDA and KENTA MUROTANI

Anticancer Research December 2022, 42 (12) 5961-5969; DOI: https://doi.org/10.21873/anticanres.16106

Main menu

User menu

Search

Immunotherapy

Pages